Minaris to manufacture Mustang Bio's lentiviral gene therapy in Europe November 23, 2020 -- Minaris Regenerative Medicine has signed an agreement with Mustang Bio to enable technology transfer and good manufacturing practice clinical manufacturing of Mustang's MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency.
Regulatory Roundup: Gene therapies, bispecific antibodies lead new approvals November 23, 2020 -- Welcome to Regulatory Roundup, a new Science Advisory Board feature that tracks recent regulatory activities in the life sciences industry. Recent approvals over the past week have included an orphan drug designation for a new gene therapy, as well as approvals for a quadrivalent flu vaccine and a hepatitis B vaccine.
Lilly, Precision BioSciences collaborate on genome editing November 20, 2020 -- Eli Lilly and Precision BioSciences have entered a research collaboration and exclusive licensing agreement to utilize Precision's proprietary Arcus genome editing platform for potential in vivo therapies for genetic disorders.
Prevail Therapeutics granted gene therapy patent November 19, 2020 -- The U.S. Patent and Trademark Office has issued a composition of matter patent (No. 10,837,028) to Prevail Therapeutics for its adeno-associated viral vector used in PR001, an experimental gene therapy program for the treatment of Parkinson's disease with mutations in the BGA1 gene and neuropathic Gaucher disease.
Cue Biopharma, Merck expand Immuno-STAT collaboration November 19, 2020 -- Cue Biopharma has extended the terms of its research collaboration and license agreement with Merck toward developing new clinical candidates for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. The research will focus on in vivo Immuno-selective targeting and alteration of T cell (STAT) biologics that are designed for targeted modulation of disease-associated T cells in immune-oncology and autoimmune diseases.
AbCellera acquires Trianni for $90M November 19, 2020 -- Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's ability to create large human antibody databases for drug discovery.
Megadalton joins Waters' Immerse Cambridge labs November 19, 2020 -- Megadalton Solutions has expanded its collaboration with Waters to bring its charge detection mass spectrometry technology to a broader set of biopharma customers by joining Waters' Immerse Cambridge lab.
Vivet, Pfizer to begin Wilson's disease gene therapy trial November 18, 2020 -- The U.S. Food and Drug Administration (FDA) has cleared Vivet Therapeutics' investigational new drug application for the Gateway study, a phase I/II study evaluating Vivet's VTX-801, a proprietary, investigational gene therapy for the treatment of Wilson's disease.
Caribou inks deal with MSK to make allogeneic therapies November 18, 2020 -- Memorial Sloan Kettering Cancer Center (MSK) has agreed to exclusively license its antibody fragments to CRISPR genome editing firm Caribou Biosciences to develop allogeneic cell therapies for cancer.